{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:07:21Z","timestamp":1792807641523,"version":"4.5.0"},"reference-count":31,"publisher":"Harborside Press, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:p>Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and\/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States. Like AML, blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a myeloid malignancy. It is a rare malignancy characterized by the aggressive proliferation of precursors of plasmacytoid dendritic cells that frequently involves the bone marrow, skin, central nervous system, and other organs and tissues. This discussion section focuses on the diagnosis and management of BPDCN as outlined in the NCCN Guidelines for AML.<\/jats:p>","DOI":"10.6004\/jnccn.2023.0025","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T15:50:40Z","timestamp":1683561040000},"page":"503-513","source":"Crossref","is-referenced-by-count":190,"title":["Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"21","author":[{"given":"Daniel A.","family":"Pollyea","sequence":"first","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Altman","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Assi","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Bixby","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Foran","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Gojo","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aric C.","family":"Hall","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Jonas","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Kishtagari","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lancet","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Maness","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mangan","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Mannis","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Mims","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Moriarty","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moaath","family":"Mustafa Ali","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadee","family":"Neff","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Nejati","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Olin","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Elizabeth","family":"Percival","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Perl","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Przespolewski","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Rao","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Shallis","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Shami","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan","family":"Stein","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapna","family":"Thota","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Uy","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[{"name":"O\u2019Neil Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly J.","family":"Cassara","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Freedman-Cass","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Stehman","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Haematologica","first-page":"58","article-title":"Incidence and characteristics of CD4(+)\/HLA DRhi dendritic cell malignancies","volume":"89","author":"Bueno C","year":"2004","unstructured":"Bueno C, Almeida J, Lucio P,  Incidence and characteristics of CD4(+)\/HLA DRhi dendritic cell malignancies. Haematologica 2004;89:58\u201369."},{"key":"B2","series-title":"Leuk Res","first-page":"21","article-title":"Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm","volume":"73","author":"Guru Murthy GS","year":"2018","unstructured":"Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res 2018;73:21\u201323."},{"key":"B3","series-title":"Blood","first-page":"3559","article-title":"Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm","volume":"125","author":"Aoki T","year":"2015","unstructured":"Aoki T, Suzuki R, Kuwatsuka Y,  Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood 2015;125:3559\u20133562."},{"key":"B4","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"16","article-title":"Treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"2016","author":"Sullivan JM","year":"2016","unstructured":"Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology Am Soc Hematol Educ Program 2016;2016:16\u201323."},{"key":"B5","series-title":"Blood","first-page":"2391","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R,  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391\u20132405."},{"key":"B6","series-title":"Leukemia","first-page":"1703","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury JD","year":"2022","unstructured":"Khoury JD, Solary E, Abla O,  The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 2022;36:1703\u20131719."},{"key":"B7","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"173","article-title":"Blastic plasmacytoid dendritic cell neoplasm","author":"Facchetti F","year":"2017","unstructured":"Facchetti F, Petrella T, Pileri S. Blastic plasmacytoid dendritic cell neoplasm. In: \nSwerdlow SH, Campo E, Harris NL, , eds WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. IARC; 2017:173\u2013177."},{"key":"B8","series-title":"Haematologica","first-page":"239","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study","volume":"98","author":"Pagano L","year":"2013","unstructured":"Pagano L, Valentini CG, Pulsoni A,  Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 2013;98:239\u2013246."},{"key":"B9","series-title":"Leukemia","first-page":"1343","article-title":"Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients","volume":"36","author":"Khanlari M","year":"2022","unstructured":"Khanlari M, Yin CC, Takahashi K,  Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia 2022;36:1343\u20131350."},{"key":"B10","series-title":"Br J Dermatol","first-page":"74","article-title":"Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?","volume":"162","author":"Dalle S","year":"2010","unstructured":"Dalle S, Beylot-Barry M, Bagot M,  Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 2010;162:74\u201379."},{"key":"B11","series-title":"N Engl J Med","first-page":"1628","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju N","year":"2019","unstructured":"Pemmaraju N, Lane AA, Sweet KL,  Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med 2019;380:1628\u20131637."},{"key":"B12","series-title":"Oncotarget","first-page":"10174","article-title":"Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy","volume":"7","author":"Mart\u00edn-Mart\u00edn L","year":"2016","unstructured":"Mart\u00edn-Mart\u00edn L, Almeida J, Pomares H,  Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget 2016;7:10174\u201310181."},{"key":"B13","series-title":"Blood","first-page":"1556","article-title":"Clinical and biologic features of CD4(+)CD56(+) malignancies","volume":"99","author":"Feuillard J","year":"2002","unstructured":"Feuillard J, Jacob MC, Valensi F,  Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002;99:1556\u20131563."},{"key":"B14","series-title":"Leuk Res","first-page":"438","article-title":"Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group","volume":"34","author":"Tsagarakis NJ","year":"2010","unstructured":"Tsagarakis NJ, Kentrou NA, Papadimitriou KA,  Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res 2010;34:438\u2013446."},{"key":"B15","series-title":"Am J Surg Pathol","first-page":"1429","article-title":"Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm","volume":"43","author":"Sukswai N","year":"2019","unstructured":"Sukswai N, Aung PP, Yin CC,  Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm. Am J Surg Pathol 2019;43:1429\u20131437."},{"key":"B16","series-title":"Cancer Cell","first-page":"764","article-title":"A druggable TCF4- and BRD4- dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm","volume":"30","author":"Ceribelli M","year":"2016","unstructured":"Ceribelli M, Hou ZE, Kelly PN,  A druggable TCF4- and BRD4- dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell 2016;30:764\u2013778."},{"key":"B17","series-title":"Leuk Lymphoma","first-page":"19","article-title":"CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies","volume":"63","author":"Wilson NR","year":"2022","unstructured":"Wilson NR, Bover L, Konopleva M,  CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Leuk Lymphoma 2022;63:19\u201330."},{"key":"B18","series-title":"Leukemia","first-page":"823","article-title":"Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm","volume":"28","author":"Menezes J","year":"2014","unstructured":"Menezes J, Acquadro F, Wiseman M,  Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 2014;28:823\u2013829."},{"key":"B19","series-title":"Leukemia","first-page":"3299","article-title":"Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin","volume":"35","author":"Batta K","year":"2021","unstructured":"Batta K, Bossenbroek HM, Pemmaraju N,  Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia 2021;35:3299\u20133303."},{"key":"B20","series-title":"Bone Marrow Transplant","first-page":"637","article-title":"What is CD4+CD56+ malignancy and how should it be treated?","volume":"32","author":"Reimer P","year":"2003","unstructured":"Reimer P, R\u00fcdiger T, Kraemer D,  What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant 2003;32:637\u2013646."},{"key":"B21","series-title":"Blood","first-page":"385","article-title":"Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"Frankel AE","year":"2014","unstructured":"Frankel AE, Woo JH, Ahn C,  Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 2014;124:385\u2013392."},{"key":"B22","series-title":"J Clin Oncol","first-page":"3032","article-title":"Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm","volume":"40","author":"Pemmaraju N","year":"2022","unstructured":"Pemmaraju N, Sweet KL, Stein AS,  Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol 2022;40:3032\u20133036."},{"key":"B23","series-title":"Am J Hematol","first-page":"283","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and HyperCVAD therapy","volume":"91","author":"Deotare U","year":"2016","unstructured":"Deotare U, Yee KW, Le LW,  Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and HyperCVAD therapy. Am J Hematol 2016;91:283\u2013286."},{"key":"B24","series-title":"Blood Adv","first-page":"3027","article-title":"Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD","volume":"6","author":"Pemmaraju N","year":"2022","unstructured":"Pemmaraju N, Wilson NR, Garcia-Manero G,  Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv 2022;6:3027\u20133035."},{"key":"B25","series-title":"Am J Hematol","first-page":"401","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo CD","year":"2018","unstructured":"DiNardo CD, Rausch CR, Benton C,  Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 2018;93:401\u2013407."},{"key":"B26","article-title":"Prescribing information for venetoclax tablets, for oral use","year":"2022","unstructured":"Prescribing information for venetoclax tablets, for oral use. 2022. Accessed March 24, 2023. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208573s027lbl.pdf"},{"key":"B27","series-title":"Cancer Discov","first-page":"156","article-title":"Blastic blasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax","volume":"7","author":"Montero J","year":"2017","unstructured":"Montero J, Stephansky J, Cai T,  Blastic blasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov 2017;7:156\u2013164."},{"key":"B28","series-title":"Blood","first-page":"440","article-title":"Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"121","author":"Roos-Weil D","year":"2013","unstructured":"Roos-Weil D, Dietrich S, Boumendil A,  Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2013;121:440\u2013446."},{"key":"B29","series-title":"Br J Haematol","first-page":"781","article-title":"Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study","volume":"179","author":"Kharfan-Dabaja MA","year":"2017","unstructured":"Kharfan-Dabaja MA, Al Malki MM, Deotare U,  Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol 2017;179:781\u2013789."},{"key":"B30","series-title":"Leukemia","first-page":"465","article-title":"Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters","volume":"37","author":"Bruch PM","year":"2023","unstructured":"Bruch PM, Dietrich S, Finel H,  Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters. Leukemia 2023;37:465\u2013472."},{"key":"B31","series-title":"Blood","first-page":"567","article-title":"North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need","volume":"141","author":"Pemmaraju N","year":"2023","unstructured":"Pemmaraju N, Kantarjian H, Sweet K,  North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood 2023;141:567\u2013578."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/5\/article-p503.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/5\/article-p503.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/5\/article-p503.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T15:55:14Z","timestamp":1683561314000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/5\/article-p503.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":31,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.0025","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}